

# Julien Edeline

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6362419/publications.pdf>

Version: 2024-02-01

144  
papers

9,882  
citations

87888

38  
h-index

39675

94  
g-index

154  
all docs

154  
docs citations

154  
times ranked

8913  
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective internal radiation therapy in older patients with hepatocellular carcinoma: a retrospective analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 417-421.	1.6	4
2	Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 262-271.	1.6	59
3	Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1-11.	2.0	3
4	Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. <i>British Journal of Cancer</i> , 2022, 126, 1394-1400.	6.4	5
5	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 77-90.	10.7	526
6	TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1599-1607.	2.0	21
7	Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. <i>Cancers</i> , 2022, 14, 1156.	3.7	6
8	MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, , 101888.	1.5	1
9	Targeted Therapies for Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1789.	3.7	7
10	Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. <i>European Journal of Cancer</i> , 2022, 164, 80-87.	2.8	12
11	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.	2.8	43
12	Patients'™ Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life. <i>Cancers</i> , 2022, 14, 179.	3.7	5
13	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	7.0	32
14	FFCD 1709-SIRTIC phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer. <i>Digestive and Liver Disease</i> , 2022, 54, 857-863.	0.9	4
15	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	17
16	Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma. <i>Liver Cancer</i> , 2022, 11, 460-473.	7.7	13
17	Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101464.	1.5	9
18	Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 17-29.	8.1	307

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021, 127, 865-874.	4.1	20
20	Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 679-687.	4.2	11
21	Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. <i>Hepatology International</i> , 2021, 15, 93-104.	4.2	28
22	FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110298.	3.2	4
23	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 153-162.	3.4	11
24	CAR-T cells and BiTEs in solid tumors: challenges and perspectives. <i>Journal of Hematology and Oncology</i> , 2021, 14, 65.	17.0	50
25	Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer. <i>Journal of Hepatology</i> , 2021, 74, 1018-1020.	3.7	2
26	Combined hepatocellular-cholangiocarcinoma "More questions than answers. <i>Liver International</i> , 2021, 41, 1186-1188.	3.9	2
27	Predictive Factors of Chemotherapy Initiation after Biliary Drainage for Advanced Biliary Tract Cancer: A Retrospective Multicenter Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 254-258.	0.9	2
28	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. <i>Clinical Therapeutics</i> , 2021, 43, 1201-1212.	2.5	4
29	Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer. <i>JAMA Network Open</i> , 2021, 4, e2113739.	5.9	19
30	Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. <i>Melanoma Research</i> , 2021, 31, 208-217.	1.2	8
31	ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3794.	3.7	16
32	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 975-983.	4.1	7
33	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102258.	7.7	45
34	Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas. <i>Current Oncology</i> , 2021, 28, 4530-4541.	2.2	1
35	Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 51.	7.1	176
36	Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. <i>Liver International</i> , 2020, 40, 215-228.	3.9	27

#	ARTICLE	IF	CITATIONS
37	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020, 84, 101936.	7.7	73
38	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	1.6	1,255
39	FOLFIRINOX Dea€Escalation in Advanced Pancreatic Cancer: A Multicenter Reala€Life Study. <i>Oncologist</i> , 2020, 25, e1701-e1710.	3.7	10
40	Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network. <i>Gynecologic Oncology</i> , 2020, 158, 666-672.	1.4	8
41	Association of Anti€Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 982.	4.1	14
42	Abscopal Effect After SIRT: It Exists, but How Could We Use It?. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1650-1651.	2.0	2
43	52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial. <i>Annals of Oncology</i> , 2020, 31, S260-S261.	1.2	15
44	78TiP KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer. <i>Annals of Oncology</i> , 2020, 31, S270-S271.	1.2	9
45	TGF-beta-associated circular RNAs in cholangiocarcinoma: mechanisms and biomarkers. <i>Journal of Hepatology</i> , 2020, 73, S632-S633.	3.7	0
46	1011P The experience associated with caregiving for patients with intermediate stage hepatocellular carcinoma (HCC) receiving transcatheter arterial chemoembolisation (TACE) treatment. <i>Annals of Oncology</i> , 2020, 31, S700-S701.	1.2	0
47	1531P FOLFIRINOX relative dose intensity (RDI) and disease control in advanced pancreatic cancer patients (APC). <i>Annals of Oncology</i> , 2020, 31, S942-S943.	1.2	0
48	Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role. <i>Cancers</i> , 2020, 12, 3182.	3.7	34
49	Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3729-3737.	1.5	56
50	PD-6 Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: A population-based, multicenter AGE0 study. <i>Annals of Oncology</i> , 2020, 31, S213-S214.	1.2	1
51	Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. <i>Lancet Oncology</i> , The, 2020, 21, 479-481.	10.7	29
52	ASO Author Reflections: Intrahepatic Cholangiocarcinoma: Downstaging Strategies Open the Gate to Surgery and Cure. <i>Annals of Surgical Oncology</i> , 2020, 27, 3738-3739.	1.5	0
53	Implementation of a molecular tumor board at a regional level to improve access to targeted therapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1234-1241.	2.2	9
54	Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1175-1181.	2.0	12

#	ARTICLE	IF	CITATIONS
55	Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90. Journal of Hepatology, 2020, 72, 1046-1048.	3.7	4
56	Adverse events of targeted therapies reported by patients with cancer treated in primary care. European Journal of General Practice, 2020, 26, 202-209.	2.0	5
57	Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA approval descriptive study with a geriatric oncology focus. Turkish Journal of Gastroenterology, 2020, 31, 695-705.	1.1	1
58	Loss of SMARCB1 expression in colon carcinoma. Cancer Biomarkers, 2020, 27, 399-406.	1.7	4
59	Tivozanib for hepatocellular carcinoma: not likely a new option. Annals of Translational Medicine, 2020, 8, 1337-1337.	1.7	0
60	Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. Annals of Oncology, 2019, 30, iv135-iv136.	1.2	10
61	CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Annals of Oncology, 2019, 30, v874-v875.	1.2	512
62	MON-PO377: Are Body Composition Parameters Associated with the Clinical Outcome of Patients with Advanced Pancreatic Cancer Receiving Fluoropyrimidine-Based Chemotherapy?. Clinical Nutrition, 2019, 38, S198.	5.0	0
63	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clinical Colorectal Cancer, 2019, 18, e394-e401.	2.3	13
64	Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2019, 51, 1337-1343.	0.9	45
65	Adjuvant capecitabine in biliary tract cancer: a standard option?. Lancet Oncology, The, 2019, 20, 606-608.	10.7	26
66	Medical treatment for cholangiocarcinoma. Liver International, 2019, 39, 123-142.	3.9	69
67	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1015-1027.	1.6	301
68	Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE). Tj ETQq0 0 0 rgBT /Overlock 10 T 658-667.	1.6	357
69	90Y-Loaded Microsphere SIRT of HCC Patients With Portal Vein Thrombosis: High Clinical Impact of 99mTc-MAA SPECT/CT-Based Dosimetry. Seminars in Nuclear Medicine, 2019, 49, 218-226.	4.6	30
70	Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study. Digestive and Liver Disease, 2019, 51, 318-320.	0.9	49
71	Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 669-676.	6.4	44
72	Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1506-1517.	6.4	15

#	ARTICLE	IF	CITATIONS
73	Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2019, 37, 4004-4004.	1.6	149
74	Negative phase 3 study of 90 Y microspheres versus sorafenib in HCC. Lancet Oncology, The, 2018, 19, e70.	10.7	16
75	Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 392-401.	6.4	58
76	A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1731-1741.	6.4	25
77	Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib's Toxicities in Hepatocellular Carcinoma. Cancer Nursing, 2018, 41, 418-423.	1.5	13
78	Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group. Annals of Oncology, 2018, 29, viii335.	1.2	0
79	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncology, The, 2018, 19, 940-952.	10.7	1,816
80	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews, 2018, 68, 16-24.	7.7	124
81	Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. Journal of Clinical Oncology, 2018, 36, 4020-4020.	1.6	9
82	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. Journal of Clinical Oncology, 2018, 36, 209-209.	1.6	30
83	Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11234.	1.0	31
84	An easy-to-use nomogram to predict overall survival (OS) at 6 months after initiation of FOLFIRINOX first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology, 2018, 36, 394-394.	1.6	0
85	Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Digestive and Liver Disease, 2017, 49, 692-696.	0.9	23
86	Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study. Annals of Oncology, 2017, 28, 1612-1617.	1.2	30
87	Does Y90 Radioembolization Prolong Overall Survival Compared With Chemoembolization in Patients With Hepatocellular Carcinoma?. Gastroenterology, 2017, 152, 1624-1625.	1.3	1
88	mRECIST for systemic therapies: More evidence is required before recommendations can be made. Journal of Hepatology, 2017, 67, 195.	3.7	5
89	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	10.7	595
90	Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. European Journal of Cancer, 2017, 86, 135-142.	2.8	19

#	ARTICLE	IF	CITATIONS
91	An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2017, 18, 1467-1476.	1.8	23
92	Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 603.e7-603.e14.	1.6	0
93	A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. Targeted Oncology, 2017, 12, 655-661.	3.6	14
94	High impact of macroaggregated albuminâ€based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with <sup>90</sup>Yâ€loaded glass microsphere radioembolization. Liver International, 2017, 37, 101-110.	3.9	71
95	Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype. Clinical Genitourinary Cancer, 2017, 15, e1-e7.	1.9	20
96	Independent association of PDâ€L1 expression with noninactivated <i>VHL</i> clear cell renal cell carcinomaâ€A finding with therapeutic potential. International Journal of Cancer, 2017, 140, 142-148.	5.1	44
97	Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. Annals of Oncology, 2017, 28, v617.	1.2	4
98	Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.. Journal of Clinical Oncology, 2017, 35, 225-225.	1.6	77
99	Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World Journal of Gastroenterology, 2017, 23, 2545.	3.3	21
100	Prognosis of advanced hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2016, 28, 433-440.	1.6	38
101	Hepatocellular carcinoma in elderly patients: challenges and solutions. Journal of Hepatocellular Carcinoma, 2016, 3, 9.	3.7	36
102	A multicentre comparison between Child Pugh and Albuminâ€Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver International, 2016, 36, 1821-1828.	3.9	85
103	High Impact of Preferential Flow on <sup>99m</sup>Tc-MAA and <sup>90</sup>Y-Loaded Microsphere Uptake Correlation. Journal of Nuclear Medicine, 2016, 57, 1829-1830.	5.0	7
104	Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). European Journal of Radiology, 2016, 85, 1445-1452.	2.6	23
105	Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocrine-Related Cancer, 2016, 23, 563-570.	3.1	24
106	Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 824-831.	6.4	15
107	Clinical impact of 99mTc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90Y-loaded microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 559-575.	6.4	121
108	Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 635-643.	6.4	74



#	ARTICLE	IF	CITATIONS
109	How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World Journal of Hepatology, 2016, 8, 1541.	2.0	10
110	Analysis of medical practices for French patients with BRAF mutant metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, e15070-e15070.	1.6	1
111	Glass Microspheres 90Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma. Clinical Nuclear Medicine, 2015, 40, 851-855.	1.3	53
112	Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. Journal of Vascular and Interventional Radiology, 2015, 26, 1874-1878.e2.	0.5	5
113	Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 16-25.	7.7	40
114	Intra-arterial Yttrium-90 Radioembolization Combined with Systemic Chemotherapy is a Promising Method for Downstaging Unresectable Huge Intrahepatic Cholangiocarcinoma to Surgical Treatment. Annals of Surgical Oncology, 2015, 22, 3102-3108.	1.5	111
115	Personalized Dosimetry with Intensification Using <sup>90</sup> Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Journal of Nuclear Medicine, 2015, 56, 339-346.	5.0	122
116	Extended liver resections for intrahepatic cholangiocarcinoma: Friend or foe?. Surgery, 2015, 157, 656-665.	1.9	26
117	Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemotherapy and Pharmacology, 2015, 75, 215-219.	2.3	23
118	Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. Acta Oncol, 2015, 54, 1833-1835.	1.8	12
119	Sorafenib or <sup>90</sup> Y-loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?. Liver International, 2015, 35, 1779-1780.	3.9	0
120	Reply: Modifying the Poor Prognosis Associated with <sup>18</sup> F-FDG Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT). Journal of Nuclear Medicine, 2015, 56, 969-969.	5.0	1
121	PDL-1 and PDL1 expressions in clear cell renal cell carcinoma (ccRCC) of metastatic patients with sunitinib first-line treatment.. Journal of Clinical Oncology, 2015, 33, e14002-e14002.	1.6	3
122	Could any pT1a,bN0M0 hormone-responsive, invasive breast carcinomas be safely treated without endocrine therapy?. Journal of Clinical Oncology, 2015, 33, 550-550.	1.6	118
123	High Prognostic Value of <sup>18</sup> F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation. Journal of Nuclear Medicine, 2014, 55, 1786-1790.	5.0	153
124	Volumetric Changes after <sup>90</sup> Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting?. Annals of Surgical Oncology, 2013, 20, 2518-2525.	1.5	76
125	A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 900-909.	2.6	20
126	Incidence of brain metastases in HER2+ gastric or esogastric junction adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 126-126.	1.6	0



#	ARTICLE	IF	CITATIONS
127	In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results. <i>Anticancer Research</i> , 2013, 33, 3871-7.	1.1	3
128	Haemolytic uremic syndrome and gemcitabine: Jaundice is not always progression in cholangiocarcinoma. <i>Acta Oncol</i> ³gica, 2012, 51, 687-688.	1.8	7
129	Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum&acirc gemcitabine regimen. <i>European Journal of Cancer</i> , 2012, 48, 1141-1146.	2.8	23
130	Dosimetry Based on <sup>99m</sup>Tc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with <sup>90</sup>Y-Loaded Glass Microspheres: Preliminary Results. <i>Journal of Nuclear Medicine</i> , 2012, 53, 255-263.	5.0	242
131	Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma. <i>Human Pathology</i> , 2012, 43, 1982-1990.	2.0	35
132	Safety and Efficacy of Sorafenib in Renal Cell Carcinoma. <i>Cancer Growth and Metastasis</i> , 2012, 5, CGM.S7526.	3.5	1
133	Cementoplasty for painful bone metastases: a series of 42 cases. <i>Medical Oncology</i> , 2012, 29, 1378-1383.	2.5	26
134	Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 872-880.	6.4	40
135	Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 907-916.	2.5	10
136	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. <i>Cancer</i> , 2012, 118, 147-156.	4.1	250
137	Looking for synergy or additivity between 188Re and sorafenib on hepatoma cell lines.. <i>Journal of Clinical Oncology</i> , 2012, 30, 247-247.	1.6	0
138	Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 48-54.	1.5	6
139	Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 246-254.	4.4	144
140	Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?. <i>British Journal of Cancer</i> , 2010, 103, 1698-1705.	6.4	69
141	Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2010, 21, 186-187.	1.2	20
142	THE PROGNOSIC IMPORTANCE OF ANGIOGENIC PHENOTYPE IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2009, 181, 111-111.	0.4	0
143	Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. <i>World Journal of Gastroenterology</i> , 2009, 15, 713.	3.3	40
144	Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	1